{"preliminary_commentary":{"by_channel":{"podcast":7,"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02854436\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["niraparib"]],"indication":"metastatic castration-resistant prostate cancer with DNA-repair gene defects","name":"GALAHAD","nct_id":"NCT02854436","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=galahad-nct02854436. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Galahad","arms":[{"description":"Participants will receive 300 milligram (mg) niraparib (3 capsules\\*100 mg) orally once daily.","label":"Niraparib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-08-16","type":"ACTUAL"},"conditions":["Prostatic Neoplasms"],"enrollment":{"count":289,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Niraparib","otherNames":["JNJ-64091742"],"type":"DRUG"}],"last_update":"2025-12-22","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-01-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation","timeFrame":"Up to 52 months"}],"references":[{"citation":"Russu A, Hazra A, Tian H, Haddish-Berhane N, Perez Ruixo JJ, Boulton M. Population Pharmacokinetics of Niraparib/Abiraterone Acetate Administered as Single-Agent Combination and Dual-Acting Tablets Plus Prednisone for Metastatic Castration-Resistant Prostate Cancer. Adv Ther. 2025 Apr;42(4):1860-1880. doi: 10.1007/s12325-025-03104-y. Epub 2025 Feb 28.","pmid":"40016438","type":"DERIVED"},{"citation":"Smith MR, Sandhu S, George DJ, Chi KN, Saad F, Thiery-Vuillemin A, Stahl O, Olmos D, Danila DC, Gafanov R, Castro E, Moon H, Joshua AM, Mason GE, Espina BM, Liu Y, Lopez-Gitlitz A, Francis P, Bevans KB, Fizazi K. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects. J Manag Care Spec Pharm. 2023 Jul;29(7):758-768. doi: 10.18553/jmcp.2023.29.7.758.","pmid":"37404070","type":"DERIVED"},{"citation":"Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Stahl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K; GALAHAD investigators. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022 Mar;23(3):362-373. doi: 10.1016/S1470-2045(21)00757-9. Epub 2022 Feb 4.","pmid":"35131040","type":"DERIVED"}],"start_date":{"date":"2016-08-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies","url":"https://clinicaltrials.gov/study/NCT02854436"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/galahad-nct02854436"}